Block copolymers and uses thereof

Abstract

An encoding/decoding apparatus and method using a low-density parity-check code (LDPC code) is disclosed. Basic column group information, serving as a set of information regarding positions of rows with weight 1, is extracted from a reference column in each column group of a predetermined parity-check matrix. Column group information transforms the positions of rows with weight 1 into positions whose lengths are within a required parity length. A parity-check matrix is generated according to the generated column group information. Data is enclosed or decoded based on the generated parity-check matrix.

What is claimed is: 
     
         1 - 46 . (canceled) 
     
     
         47 . A supramolecular structure comprising a (i) a block copolymer comprising a positively charged block, and (ii) a nucleic acid, wherein said supramolecular structure has a maximal diameter of 60 nm or less. 
     
     
         48 . The supramolecular structure of  claim 47 , wherein said supramolecular structure is a molecule or a vesicle. 
     
     
         49 . The supramolecular structure of  claim 47 , wherein said block copolymer further comprises a hydrophilic block or a hydrophobic block. 
     
     
         50 . The supramolecular structure of  claim 49 , wherein said block copolymer further comprises a hydrophilic block and a hydrophobic block. 
     
     
         51 . The supramolecular structure of  claim 47 , wherein said maximal diameter is 40 nm or less. 
     
     
         52 . The supramolecular structure of  claim 47 , wherein said block copolymer comprises PEG-PPS-PEI. 
     
     
         53 . The supramolecular structure of  claim 47 , wherein said nucleic acid comprises a single-stranded oligonucleotide, a short interfering RNA, an aptamer, or plasmid DNA. 
     
     
         54 . A method of transfecting a cell with a nucleic acid comprising contacting said cell with the supramolecular structure of  claim 47 . 
     
     
         55 . A block copolymer comprising PEG-PPS-PEI. 
     
     
         56 . The block copolymer of  claim 55 , wherein the PPS block and the PEI block are attached via a bond that is labile in an endosome. 
     
     
         57 . The block copolymer of  claim 56 , wherein said bond comprises a disulfide bond, vinyl ether, orthoester, acyl hydrazone, or a —N—PO 3 — group. 
     
     
         58 . The block copolymer of  claim 55 , further comprising a nucleic acid complexed to said PEI. 
     
     
         59 . A pharmaceutical composition comprising the block copolymer of  claim 55  and a pharmaceutically acceptable diluent. 
     
     
         60 - 78 . (canceled) 
     
     
         79 . The supramolecular structure of  claim 47 , wherein said block copolymer further comprises a PPS block. 
     
     
         80 . The supramolecular structure of  claim 47 , wherein said positively charged block is PEI. 
     
     
         81 . The supramolecular structure of  claim 47 , wherein said supramolecular structure further comprises PEG-PPS.